Monte Rosa Therapeutics (GLUE) Share-based Compensation Growth (1y) (2021 - 2026)
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 71.86% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -3.46% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -7.69% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | -8.89% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | -22.43% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -4.01% |
| 10 | Monte Rosa Therapeutics | 1.41 Bn | 781.72 Mn | - | 4.93% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.93% |
| Mar 31, 2026 | 5.53% |
| Dec 31, 2025 | -3.58% |
| Sep 30, 2025 | 28.92% |
| Jun 30, 2025 | 31.68% |
| Mar 31, 2025 | 29.39% |
| Dec 31, 2024 | 9.70% |
| Sep 30, 2024 | -64.98% |
| Jun 30, 2024 | -69.56% |
| Mar 31, 2024 | 15.99% |
| Dec 31, 2023 | 22.49% |
| Sep 30, 2023 | 1.53% |
| Jun 30, 2023 | 6.76% |
| Mar 31, 2023 | 42.10% |
| Dec 31, 2022 | 79.20% |
| Sep 30, 2022 | 24.90% |
| Jun 30, 2022 | 538.15% |
| Mar 31, 2022 | 2,719.42% |
| Dec 31, 2021 | 823.38% |
| Sep 30, 2021 | 57,900.00% |